Combining ibogaine with selective serotonin reuptake inhibitors (SSRIs) carries serious, potentially life-threatening risks — most critically serotonin syndrome and compounded cardiac effects. Anyone currently taking an SSRI who is considering ibogaine treatment must complete a medically supervised washout period before proceeding, and must disclose all medications to their treatment provider without exception.

Why Does the Ibogaine–SSRI Combination Pose Such a Serious Risk?

Ibogaine acts on multiple receptor systems simultaneously — including serotonin transporters (SERT), sigma receptors, and opioid receptors — making it pharmacologically complex. SSRIs work by blocking SERT to increase synaptic serotonin levels. When ibogaine is layered on top of an active SSRI, the combined serotonergic load on the brain can become excessive.

The result may be serotonin syndrome, a potentially fatal condition characterized by agitation, rapid heart rate, high blood pressure, high body temperature, tremor, and in severe cases, seizures or death. Ibogaine also prolongs the QTc interval on the electrocardiogram — a cardiac electrical measurement — and some SSRIs (notably citalopram and escitalopram) independently prolong QTc as well. The overlap creates a compounded cardiac risk that experienced clinicians treat as a hard contraindication.

Safety Warning: Serotonin syndrome can escalate to a medical emergency within hours. Never combine ibogaine with an SSRI, SNRI, MAOI, or other serotonergic agent without explicit clearance from a physician experienced in ibogaine protocols. This is not a risk that can be managed through dose reduction alone.

Which SSRIs and Related Drugs Are Involved?

The concern extends beyond the classic SSRI category. Any medication that increases serotonin availability or activity should be evaluated carefully before ibogaine administration. Commonly prescribed agents include:

  • SSRIs: fluoxetine (Prozac), sertraline (Zoloft), escitalopram (Lexapro), citalopram (Celexa), paroxetine (Paxil), fluvoxamine (Luvox)
  • SNRIs: venlafaxine (Effexor), duloxetine (Cymbalta), desvenlafaxine (Pristiq)
  • Other serotonergic agents: mirtazapine, trazodone, buspirone, tramadol, St. John's Wort, lithium (which sensitizes serotonin receptors)
  • MAOIs: phenelzine, tranylcypromine, and the antibiotic linezolid or the dye methylene blue, both of which have MAOI-like properties

Fluoxetine deserves special mention because its active metabolite, norfluoxetine, has a half-life of four to six days — meaning the drug remains pharmacologically active in the body for weeks after the last dose. This makes fluoxetine washout periods substantially longer than those for other SSRIs.

How Long Is the Required Washout Period?

Washout period guidelines vary by drug and by clinical protocol, but experienced ibogaine providers generally follow pharmacokinetic principles based on drug half-lives. A standard rule of thumb is to allow five half-lives to pass before ibogaine administration, though some protocols extend this further for safety margin.

Medication Approximate Half-Life Typical Washout Estimate
Sertraline 26 hours 5–7 days
Escitalopram 27–32 hours 5–7 days
Paroxetine 21 hours (but nonlinear kinetics) 7–14 days
Venlafaxine 5 hours (parent); 11 hours (metabolite) 5–7 days
Fluoxetine 1–4 days; metabolite 4–6 days 4–6 weeks

These are estimates, not prescriptions. Individual metabolism, dose history, duration of use, and other factors all influence how quickly a drug clears the body. A treating physician should order blood work or use clinical judgment to confirm adequate clearance before any ibogaine session proceeds.

Does Tapering Off an SSRI Carry Its Own Risks?

Yes — and this is a dimension of the ibogaine-SSRI conversation that is frequently underestimated. Abruptly stopping an SSRI, especially after long-term use, can cause SSRI discontinuation syndrome: dizziness, electric shock sensations (commonly called "brain zaps"), irritability, insomnia, nausea, and emotional instability. These symptoms can be confused with, or compound, the challenging psychological effects of ibogaine itself.

Reputable ibogaine clinics require that the SSRI taper be completed — and the patient stabilized — well in advance of treatment. This typically means the washout period begins only after the final tapered dose, not during the taper itself. Tapering should always be done under the guidance of the prescribing physician or psychiatrist, with ibogaine providers informed of every step in the process.

Do Not Self-Taper: Stopping an SSRI without medical supervision can destabilize mood, trigger depressive episodes, or cause discontinuation symptoms that complicate ibogaine preparation. Coordinate between your prescribing physician and ibogaine provider before changing your medication regimen.

How Do Reputable Clinics Screen for SSRI Use?

Established ibogaine clinics — currently operating legally in countries such as Mexico, Portugal, the Netherlands, and Canada — conduct comprehensive pre-treatment medical screening that includes a full medication history, ECG (electrocardiogram), liver function tests, and in some cases, plasma drug level testing. Providers trained in ibogaine safety protocols treat concurrent SSRI use as an absolute contraindication until the washout is confirmed complete.

Red flags that should prompt a prospective patient to seek a different provider include: a clinic that does not ask about psychiatric medications, a clinic that minimizes the washout requirement, or any provider offering to administer ibogaine while a patient is actively taking serotonergic drugs. These are not acceptable risk tradeoffs — they are signs of inadequate medical oversight. Research published in the American Journal of Drug and Alcohol Abuse (Noller et al., 2018) and adverse event case reviews consistently identify polypharmacy and cardiac risk factors as primary contributors to serious ibogaine-related incidents.

What About Ibogaine's Legal Status in the US?

Ibogaine is classified as a Schedule I controlled substance under the US Controlled Substances Act, meaning it has no currently accepted medical use in the United States and is illegal to possess, distribute, or administer domestically outside of a DEA-approved research context. Americans who seek ibogaine treatment typically travel to licensed clinics in other jurisdictions. The Veterans Ibogaine Act, passed in late 2024, directed the Department of Defense to fund clinical trials of ibogaine for veterans with PTSD and traumatic brain injury — signaling growing federal interest, but not a change in Schedule I status. Consulting an attorney familiar with drug policy is advisable for anyone navigating this legal landscape.

Frequently Asked Questions

No dose of ibogaine is considered safe in combination with an active SSRI. The serotonin syndrome risk and cardiac QTc prolongation are not purely dose-dependent in a way that allows a "safe" lower threshold. Medically supervised clinics treat concurrent SSRI use as a hard contraindication regardless of the intended ibogaine dose.
Almost certainly not. Even fast-clearing SSRIs like sertraline require approximately five to seven days for adequate washout, and fluoxetine requires four to six weeks due to its long-acting metabolite. Any reputable clinic will require documented washout time and may test plasma levels before proceeding.
Yes. St. John's Wort (Hypericum perforatum) has serotonergic activity and also induces CYP3A4 and CYP2C9 liver enzymes, which can alter ibogaine metabolism. It should be disclosed to your provider and discontinued — with appropriate washout — before ibogaine administration.
Serotonin syndrome is a drug reaction caused by excess serotonergic activity in the nervous system. Symptoms include agitation, confusion, rapid heart rate, high blood pressure, dilated pupils, muscle twitching or rigidity, excessive sweating, diarrhea, and high body temperature. Severe cases can involve seizures, irregular heartbeat, and loss of consciousness. It is a medical emergency requiring immediate care.
Ibogaine and its metabolite noribogaine have their own elimination timeline — noribogaine can persist in the body for days to weeks depending on dose and individual metabolism. Restarting an SSRI too quickly after ibogaine could still carry interaction risk. This decision should be made with a physician who is aware of when ibogaine was administered and at what dose.
Yes, there is an additional pharmacokinetic layer. Ibogaine is primarily metabolized by CYP2D6, and it also inhibits this enzyme. Several SSRIs — especially paroxetine and fluoxetine — are strong CYP2D6 inhibitors themselves. This means the presence of either drug can slow the clearance of the other, causing higher-than-expected plasma levels and extending the period of risk.
No SSRI is currently considered safe to combine with ibogaine. While some SSRIs clear the body faster than others (making the washout period shorter), all carry serotonin syndrome risk when combined with ibogaine's serotonergic activity. Escitalopram and citalopram add QTc prolongation risk on top of serotonergic concerns, making them particularly high-risk pairings.

The intersection of ibogaine and SSRIs is one of the most clinically significant safety topics in the field. If you are considering ibogaine treatment and currently take any serotonergic medication, the single most important step you can take is to speak openly with both your prescribing physician and a medically experienced ibogaine provider — ideally before making any changes to your current medications. Coordinated, transparent medical oversight is not optional in this context; it is what separates a therapeutic experience from a preventable crisis.

Informational only. Not medical or legal advice. Ibogaine is Schedule I in the US. Consult qualified professionals.